TABLE 6

Summary of Recommendations

Disease	Objective	Recommended?	Net benefits?	Overall quality
Breast cancer
Diagnosis		No	Uncertain	Moderate
Staging	Local (axillary lymph node) staging	No	No	Moderate
Recurrence	Detection of metastases	Yes, for patients clinically suspected of metastasis/recurrence	Yes	Moderate
Colorectal cancer
Diagnosis		No	No	Low
Staging	Liver metastasis staging	Yes	Yes	Moderate
Recurrence	Detection of metastases or local recurrence	Yes	Yes	Moderate
Esophageal cancer
Diagnosis		No^*
Staging	Pretreatment staging	Yes, especially to detect distant metastases	Yes	Moderate
Recurrence		No^*
Head and neck cancer
Diagnosis	Diagnosis of unknown primary tumor	Yes	Yes	Moderate
	Diagnosis of head and neck tumors	No	Uncertain	Low
Staging		Yes	Yes	Moderate
Recurrence		Yes	Yes	Moderate
Lymphoma
Diagnosis		No^*
Staging	General staging	Suggested	Yes	Low
	Bone marrow staging	Yes	Yes	Moderate
Recurrence^†		Yes, for HD and NHL after completion of initial treatment	Yes	Moderate
			Yes	Low
		No, for general follow-up of asymptomatic HD or NHL	No	Low
Lung cancer
Diagnosis		SNP: yes	Yes	Moderate
Staging		NCLC: yes	Yes	High
		SCLC: no recommendation is possible	Uncertain	Low
Recurrence		No^*
Melanoma
Diagnosis		No^*
Staging		Yes, for distant metastases	Yes	Moderate
Recurrence		No^*
Pancreatic cancer
Diagnosis		Yes, for cases in which CT is inconclusive	Yes	Moderate
Staging		No^*
Recurrence		No^*
Sarcoma
Diagnosis		No recommendation is possible	Uncertain	Low
Staging		No recommendation is possible	Uncertain	Low
Recurrence		No^*
Thyroid cancer
Diagnosis		No^*
Staging		No^*
Recurrence		Yes, if ¹³¹I whole-body findings are negative and thyroglobulin is elevated	Yes	Low
		No, if ¹³¹I whole-body findings are negative and thyroglobulin is normal (surveillance)	No	Low
Unknown primary tumor
Diagnosis		Yes	Yes	Low
Staging		No^*
Recurrence		No^*

↵* Synthesis of research data has not been performed.
↵† Restaging/detection of relapse; assessment of residual mass or progression after completion of initial treatment.